Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Benserazide Hydrochloride
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase I/ Phase II
Sponsor : National Heart, Lung, and Blood Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
The BENeFiTS Trial in Beta Thalassemia Intermedia
Details : Benserazide is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of beta-Thalassemia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 16, 2020
Lead Product(s) : Benserazide Hydrochloride
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I/ Phase II
Sponsor : National Heart, Lung, and Blood Institute
Deal Size : Inapplicable
Deal Type : Inapplicable